Warfarin Dose Adjustment by INR
Warfarin Dose Adjustment by INR
Where an INR sits against its target range, and what the guidelines actually say to do about it — including the most useful answer, which is often to change nothing. Warfarin’s effect lags by days, so dose changes are judged on the weekly total rather than on a single reading.
Warfarin dose adjustment
INR vs target → actionINR 1.4, target range 2.0 to 3.0, no bleeding
How warfarin dosing works, and why this page gives no percentage
Published guidance describes changes of roughly 5% to 20% of the weekly total.
- the lag
- warfarin acts by depleting vitamin K-dependent factors, and factor II has a half-life of around 60 hours. The full effect of a dose change takes several days to appear, so an INR taken the day after a change reflects the old dose
- why weekly
- the weekly total is what determines the steady-state effect. Altering one day's tablet and leaving the rest changes the weekly total by a seventh of that change, which is usually not what was intended
- why no single percentage here
- the adjustment tables in circulation are largely unattributed and their bands overlap — 5 to 20%, 5 to 15% and 5 to 10% are all quoted for adjacent INR ranges by different sources. Rather than average them into a figure with no provenance, this page reports the relationship to target and the actions named guidelines give, and defers the percentage to your own anticoagulation service's protocol
- the high-INR arms
- come from the British Society for Haematology guideline on oral anticoagulation with warfarin, fourth edition, which gives concrete doses rather than percentages
- time in therapeutic range
- the outcome measure that matters. It is improved by stability, not by responsiveness, which is why a single out-of-range INR in a stable patient is often best left alone
Worked example
INR 1.4, target range 2.0 to 3.0, no bleeding
1.4 is below the lower limit of 2.0
It is more than 0.5 below it, so this is not a marginal result — the patient is genuinely sub-therapeutic
Check adherence and the timing of the last dose first; missed doses are commoner than any other explanation
Increase the total weekly dose against the local protocol, not a single day's tablet
Decide about bridging from the indication: usual after a recent venous thromboembolism or with a mechanical mitral valve, not usual in stable atrial fibrillation
Recheck in about a week — sooner than that and the result still reflects the old dose
What the guidelines say for a high INR
| Situation | Action | Source |
|---|---|---|
| INR above 5.0, not bleeding | Withhold one or two doses of warfarin and reduce the maintenance dose | BSH, oral anticoagulation with warfarin, 4th edition |
| INR above 8.0, not bleeding | Give 1 to 5 mg of oral vitamin K; repeat if the INR is still high after 24 hours | BSH, 4th edition |
| Non-major bleeding | Give 1 to 3 mg of intravenous vitamin K | BSH, 4th edition |
| Major bleeding | Stop warfarin; four-factor prothrombin complex concentrate 25 to 50 units/kg plus 5 mg intravenous vitamin K | BSH, 4th edition |
| Out of range without bleeding, INR below 5 | Adjust the total weekly dose, commonly described as a 5 to 20% increase or decrease | ACCP-based guidance; the exact percentage differs between protocols |
Before changing the dose, ask these
| Question | Why it matters |
|---|---|
| Has the patient missed or doubled any doses? | Adherence explains more out-of-range INRs than pharmacokinetics does, and a dose increase on top of poor adherence is dangerous once adherence improves |
| Any new medicine, including over the counter? | Antibiotics, azole antifungals, amiodarone, miconazole oral gel, NSAIDs and many herbal preparations all interact. A new antibiotic is the single commonest cause of a sudden rise |
| Any change in alcohol intake? | Binge drinking raises the INR acutely; sustained heavy intake with liver disease is less predictable |
| Any change in diet? | Large swings in green vegetable intake change vitamin K availability. Consistency matters more than avoidance |
| Any intercurrent illness? | Fever, diarrhoea, poor oral intake, acute heart failure and new liver dysfunction all raise the INR |
| Is this one reading or a trend? | A single reading a little out of range in a stable patient often needs no change. A trend across several readings does |
Judge the weekly total, not the single reading
Warfarin is dosed against a moving target with a delayed response, and most of the errors in managing it come from forgetting the delay. The drug works by depleting the vitamin K-dependent clotting factors, and prothrombin has a half-life of around sixty hours, so the full effect of a dose change takes several days to show up in the INR. An INR checked the day after an adjustment is still reporting on the old dose. That is why doses are adjusted as a total weekly amount and why the interval before rechecking is measured in days to a week, not in hours.
The second thing that follows from the pharmacology is less intuitive: a single out-of-range INR often needs no dose change at all. An individual patient's INR fluctuates around its own mean even on a perfectly constant dose, so a reading of 3.2 on a target of 2 to 3, in someone who has been stable for months, is more likely to be ordinary variation than evidence that the dose is wrong. Reacting to each reading produces oscillation — a reduction, then a sub-therapeutic result, then an increase, then a high one — and time in therapeutic range, which is the measure that actually predicts stroke and haemorrhage, falls. In a consistently stable patient, guidance supports extending the testing interval to as long as twelve weeks rather than tightening it.
When an adjustment is warranted, it is made to the weekly total. Changing one day's tablet alters the weekly dose by a seventh of that change, which is rarely what was intended. Published guidance describes changes of roughly 5 to 20% of the weekly dose, with the smaller end for results close to range, but the exact percentage differs between protocols and the widely copied nomograms do not carry an attributable source. This page therefore does not compute one. It tells you where the INR sits against target and what the named guidelines say to do; the percentage comes from your own anticoagulation service's protocol, which is also the document that will say whether to bridge with a low-molecular-weight heparin while the INR is sub-therapeutic.
An INR above 8, or any bleeding, is a different problem and is not solved by adjusting a weekly dose. The British Society for Haematology gives specific actions: withhold one or two doses and reduce the maintenance dose above an INR of 5.0 without bleeding; 1 to 5 mg of oral vitamin K above 8.0; 1 to 3 mg of intravenous vitamin K for non-major bleeding; and for major bleeding, a four-factor prothrombin complex concentrate at 25 to 50 units/kg together with 5 mg of intravenous vitamin K. The vitamin K is not optional in that last case — the concentrate corrects the INR for hours and warfarin lasts days, so without it the patient rebounds. Before increasing or decreasing anything, look for the reason: a newly started antibiotic or azole antifungal, amiodarone, a change in alcohol or diet, an intercurrent illness, or simply missed doses will explain the majority of unstable INRs. This calculation supports a prescriber's decision against the local anticoagulation protocol and does not replace it. The dose that is given is the one the responsible clinician writes on the chart, against that hospital's own nomogram and its own laboratory's calibration.
Frequently asked questions
How much should a warfarin dose be changed for an out-of-range INR?
By a percentage of the total weekly dose, commonly described in ACCP-based guidance as a 5 to 20% increase or decrease, with the smaller end used for results close to range. The exact figure differs between published protocols, so use your own anticoagulation service's table rather than a generic one, and recheck in about a week.
Should a single INR slightly out of range be acted on?
Often not. An individual's INR fluctuates around its own mean on a constant dose, and warfarin's effect lags by days, so adjusting after every reading produces oscillation and lowers time in therapeutic range. Confirm the result, check adherence and interacting medicines, and recheck in a week before changing anything.
What should be done for an INR above 8?
BSH recommends stopping warfarin and giving 1 to 5 mg of oral vitamin K if there is no bleeding, repeated if the INR remains high at 24 hours, with daily rechecks until it is below 5.0. With non-major bleeding, give 1 to 3 mg intravenously. This is a reversal problem, not a dose adjustment problem.
How is major bleeding on warfarin reversed?
With a four-factor prothrombin complex concentrate at 25 to 50 units/kg together with 5 mg of intravenous vitamin K, per BSH. Both are required: the concentrate corrects the INR within minutes but is cleared within hours, whereas warfarin's effect persists for days, so vitamin K prevents the INR rebounding.
Why change the weekly dose rather than a single day's tablet?
Because the weekly total determines the steady-state anticoagulant effect. Altering one day's tablet changes the weekly total by only a seventh of that amount, which usually undershoots the intended adjustment, and it makes the regimen harder for the patient to follow correctly.
Related calculators
References
- Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin — fourth edition. Br J Haematol. 2011;154(3):311–324.
- Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e152S–e184S.
- Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257–3291.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.